Eli Lilly and Company (LLY) announced that Zepbound injection is now available. It is indicated for adults with obesity, or those who are overweight and also have weight-related medical problems. The company said, following the FDA approval, people living with obesity can now access Zepbound in six doses through a prescription.
Effective Dec. 1, 2023, Zepbound was added to the National Preferred Formulary for Express Scripts and Cigna Healthcare. Effective Dec. 15, 2023, it will be added to Cigna Healthcare's commercial formularies.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.